MétaCan
Menu
Back to cohort
Record W4407265667 · doi:10.1093/ndt/gfaf022

COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics

2025· article· en· W4407265667 on OpenAlexfundno aff
Rajiv Agarwal, Jennifer B. Green, Hiddo J.L. Heerspink, Johannes F.E. Mann, Janet B. McGill, Amy K. Mottl, Julio Rosenstock, Peter Rossing, Muthiah Vaduganathan, Meike Brinker, Robert Edfors, Na Li, Markus F. Scheerer, Charlie Scott, Masaomi Nangaku, Agostino Consoli, Ahmed Awad, Alfonso Soto, Ali Iranmanesh, An Nollet, Ankur Doshi, Anna Maria Veronelli, Ashar Luqman, Bernhard R. Winkelmann, Bruce Baker, Bruno Guerci, Bruno Van Vlem, Bruno Vergès, Byung‐Wan Lee, Carolina Solis‐Herrera, Chandrashekar Matad, Chang Beom Lee, Chien‐Te Lee, Chiz‐Tzung Chang, Choon Hee Chung, C Kloos, Christoph Axthelm, Claus Bogh Juhl, Cristina Castro, Cristóbal Morales, Csaba P. Kövesdy, Daishiro Yamada, Dana Mitchell, David E. Gaskin, Der‐Cherng Tarng, Dinesh Khullar, Pierre‐Louis Carron, Manisha Sahay, Elie Sahyouni, Emanuele Bosi, Enrico Fiaccadori, Eun Young Lee, Faiad Adawi, Fernando Cereto Castro, Francis Duyck, Francisco Martínez Debén, Fumi Umeoka, Ganapathi Bantwal, Genya Aharon‐Hananel, Germán T. Hernández, Giancarlo Tonolo, Giuseppe Mazza, Giuseppe Penno, Gloria Ortiz, Guillermo E. Umpierrez, Hanane Bourarich, Hansraj Alva, Harold L. Miller, Harvey Serota, Hideo Kanehara, Hidetoshi Kanai, Hitesh K. Mehta, Idit F. Liberty, Khalid Iqbal, Jae Myung Yu, J Probst, Jay H. Shubrook, Jean‐Pierre Fauvel, Jeroen van der Net, Jesper Nørgaard Bech, J.L. Teruel, Jose Mandry, Juan Diego Mediavilla, Jugal Bihari Gupta, Julie Silverstein, Julio Wainstein, Ju‐Ying Jiang, Keung Lee, Klaus Busch, Kunihisa Kobayashi, Leslie Spry, Lutz Stemler, Kwan‐Dun Wu, María José Soler Romeo, Mariana Garcia‐Touza, Marijn M. Speeckaert, Markus van der Giet, Masahiko Ochi, Masao Ishii, Matthew Ray, Mazen Elias, Minesh Rajpal, Ming Ju Wu, Mirjam A. Lips, Mohamed A. El-Shahawy, Nauman Shahid, Nimer Assy, Nomy Levin-Iaina, O. Dupuy, Olivier Moranne, Osvaldo Brusco, Pablo Pergola, Pal Atanu, Paola Ponzani, Paul A Rootjes, Pedro Velasquez Mieyer, Peter Doubel, Peter T Luik, Pieter Gillard, Piotr Lazowski, Prabha Dadala Ratna, R. N. Singh, Rekha John, Richard Powell, Richard Tytus, Roberta Poli, R Cimino, Roberto Trevisan, Salvatore De Cosmo, Sameh Fikry, Saurabh Agarwal, Scott Hines, Sean Peterson, Seok Joon Shin, Sharma Balram, Shih‐Te Tu, Shivinder Jolly, Siddharth Mavani, Soo Ting Joyce Lim, Sree Bhushan Raju, Reddy Sreedhar, Steve Fordan, SUBHASH KUMAR WANGNOO, Sung-Gyun Kim, Syed Pervaiz, Takeshi Osonoi, Terumasa Hayashi, Thorsten Koch, Thure Krarup, Tuan-Huy Tran, Tushar Bandgar, Vernekar Ritesh, Veronica Resi, Wajdi Al-Shweiat, Wayne Kotzker, William Beaubien‐Souligny, William Kaye, William H. Yang, Woo-Je Lee, Yoshihide Hirohata, Yoshimitsu Yamasaki, You‐Cheol Hwang, Young Min Cho, Young Sun Kang

Bibliographic record

VenueNephrology Dialysis Transplantation · 2025
Typearticle
Languageen
FieldMedicine
TopicHormonal Regulation and Hypertension
Canadian institutionsnot available
FundersRelypsaAmerican RegentBayer, United KingdomChugai PharmaceuticalMannKind CorporationCytokineticsFresenius Medical Care North AmericaAstellas PharmaNovo NordiskMcMaster UniversityDaiichi-SankyoImpulse DynamicsIdorsia PharmaceuticalsNational Institutes of HealthRegeneron PharmaceuticalsAkebia TherapeuticsBristol-Myers SquibbEli Lilly and CompanyAstraZenecaCSL BehringAlexion PharmaceuticalsAlnylam PharmaceuticalsBayerGilead SciencesBayer HealthCareEuropean CommissionSanofiAmgenPfizer
KeywordsEmpagliflozinMedicinePlaceboClinical endpointInternal medicineKidney diseaseConfidence intervalHazard ratioRandomized controlled trialType 2 diabetesDiabetes mellitusRandomizationEndocrinology

Abstract

fetched live from OpenAlex

BACKGROUND: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, and sodium-glucose cotransporter 2 inhibitors (SGLT2is) both reduce chronic kidney disease (CKD) progression and improve kidney/cardiovascular (CV) outcomes. The CONFIDENCE (COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint) study (NCT05254002; EudraCT 2021-003037-11) hypothesis is that early combination of finerenone and empagliflozin, an SGLT2i, is superior to either drug alone in reducing urine albumin-to-creatinine ratio (UACR) over 6 months. METHODS: CONFIDENCE is an ongoing, fully enrolled, randomized, controlled, double-blind, multicentre phase 2 clinical trial in adults (≥18 years of age) with CKD and type 2 diabetes (T2D), estimated glomerular filtration rate (eGFR) of 30-90 mL/min/1.73 m2 and UACR of ≥100 to <5000 mg/g. Participants taking the clinically maximum tolerated dose of a renin-angiotensin system inhibitor for >1 month at screening were eligible. Participants were randomized 1:1:1 to once-daily finerenone plus empagliflozin, finerenone plus placebo, or empagliflozin plus placebo; doses were 10 mg once daily for empagliflozin and 10 or 20 mg once daily for finerenone, depending on eGFR at baseline. Randomization was stratified by eGFR (<60 or ≥60 mL/min/1.73 m2) and UACR (≤850 or >850 mg/g). The primary efficacy outcome is the relative change in UACR from baseline at Day 180. RESULTS: There were 818 participants randomized across 143 sites from 14 countries between July 2022 and August 2024. Mean (standard deviation) eGFR was 54.2 (17.1) mL/min/1.73 m2. Median (interquartile range) UACR was 583 (292, 1140) mg/g. Mean (standard deviation) HbA1c was 7.3 (1.2)%. Mean systolic/diastolic blood pressure was 135.2/77.3 mmHg. Glucagon-like peptide-1 receptor agonists and insulin were used by 182 (23%) and 313 (39%) participants, respectively. Atherosclerotic CV disease, diabetic retinopathy and a history of heart failure were present in 223 (28%), 126 (16%) and 30 (4%) participants, respectively. CONCLUSIONS: The CONFIDENCE trial enrolled a diverse population with CKD and T2D, and will determine the impact of simultaneous initiation of combination finerenone and an SGLT2i versus individual therapy on potentially mitigating the progression of CKD in people with T2D. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT05254002; EudraCT 2021-003037-11.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.070
Threshold uncertainty score0.392

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.028
GPT teacher head0.326
Teacher spread0.299 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations21
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueNephrology Dialysis TransplantationSame topicHormonal Regulation and HypertensionFrench-language works237,207